Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 16 November 2022 to Question 83513 on Coronavirus: Vaccination, for what reasons covid-19 vaccines which have a conditional marketing authorisation such as (a) Spikevax, Moderna, (b) Spikevax bivalent, Moderna, (c) Comirnaty bivalent, Pfizer-BioNTech and (d) Novavax, Nuvaxovid can continue to be used now that the Comirnaty vaccine has full marketing authorisation.

The granting of a full Marketing Authorisation for one product does not affect the Conditional Marketing Authorisations (CMA) of others. CMAs are used for products which prevent or treat serious and life-threatening diseases where no satisfactory treatment methods are available or where the product offers a significant therapeutic advantage. The Medicines and Healthcare products Regulatory Agency may grant a CMA where comprehensive clinical data is not yet complete although it is judged that such data will become available shortly.